Fitebac Cavity Cleanser
FiteBac® Antimicrobial Cavity Cleanser represents the 1st FDA cleared antimicrobial cavity cleanser
MARIETTA, Ga. (PRWEB)
October 15, 2020
Largent Health, LLC announced today the U.S. commercial availability of FiteBac® Antimicrobial Cavity Cleanser, with 2% K21. Dental cavity cleansers are used for cleansing and moistening/re-wetting of prepared dental surfaces prior to completion of tooth restoration. The company included in their FDA application, compelling data supporting antimicrobial activity that reduces dentally relevant microbes (1-3).
FiteBac® technology exemplifies the marriage of antimicrobial technology to material science, enabling the manufacture of modern materials offering sustained, non-leaching antimicrobial protection across a broad range of products. “FiteBac® Antimicrobial Cavity Cleanser represents the 1st FDA cleared antimicrobial cavity cleanser”, said Kirk Kimmerling, DDS, co-inventor of FiteBac® technology. “By utilizing a targeted approach to address local microbial issues, dental products incorporating FiteBac® technology have the potential to address local microbial issues within the oral cavity while minimizing potential negative impacts on the oral microbiome, a key component to good overall health”.
FiteBac® Antimicrobial Cavity Cleanser, containing the patented antimicrobial K21, is intended to become part of the restoration/dentin interface by copolymerizing with the dental adhesive. Research shows FiteBac® Cavity Cleanser can not only help remove debris in carious lesion preparations, but also help reduce the presence of dentally relevant organisms within the prepared tooth structure and also penetrate exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin surface.
“With the commercial introduction of FiteBac® Antimicrobial Cavity Cleanser, the first in a planned line of targeted antimicrobial and/or biofilm reducing dental products under development at Largent Health, we aim to provide new tools for the dental professional to specifically target microbial issues and their complications within the oral cavity”, said John W. Sharkey, Ph.D., Chief Executive Officer at Largent Health. “FiteBac® Antimicrobial Cavity Cleanser offers the dental professional a differentiated product which, besides helping to ensure the restoration site is clear of carious debris, allows them to directly address residual microbial contamination within the prepared tooth structure.”
To learn more about how FiteBac® technology is being developed for medical and dental applications please visit http://www.LargentHealth.com. Dentists interested in ordering FiteBac® Antimicrobial Cavity Cleanser are invited to visit http://www.FiteBacDental.com.
About Largent Health LLC
Largent Health, LLC, based in Marietta, GA, is a private company dedicated to the research, development and commercialization of innovative healthcare products incorporating FiteBac® technology, a superior approach to antimicrobial protection. To learn more please visit http://www.LargentHealth.com. To learn more about FiteBac® dental products please visit http://www.FitebacDental.com.
Contact Information
John W. Sharkey
Largent Health LLC
johnsharkey@fitebac.com
https://www.FiteBacDental.com
1) Gou YP, Li JY, Meghil MM, et al. Quaternary ammonium silane-based antibacterial and anti-proteolytic cavity cleanser. Dent Mater. 2018;34(12):1814-1827.
2) Daood U, Burrow MF, Yiu CKY. Effect of a novel quaternary ammonium silane cavity disinfectant on cariogenic biofilm formation. Clin Oral Investig. 2020;24(2):649-661.
3) Data on File
Share article on social media or email: